摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

[(2R,3S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-2-(methoxymethyl)oxolan-3-yl] dihydrogen phosphate

中文名称
——
中文别名
——
英文名称
[(2R,3S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-2-(methoxymethyl)oxolan-3-yl] dihydrogen phosphate
英文别名
——
[(2R,3S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-2-(methoxymethyl)oxolan-3-yl] dihydrogen phosphate化学式
CAS
——
化学式
C10H16N3O7P
mdl
——
分子量
321.22
InChiKey
KDEYIGMYYNROAU-LKEWCRSYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -2.5
  • 重原子数:
    21
  • 可旋转键数:
    5
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.6
  • 拓扑面积:
    144
  • 氢给体数:
    3
  • 氢受体数:
    7

文献信息

  • Mutant pores
    申请人:Oxford Nanopore Technologies Ltd.
    公开号:US10167503B2
    公开(公告)日:2019-01-01
    The invention relates to mutant forms of Msp. The invention also relates to polynucleotide characterization using Msp.
    本发明涉及突变形式的 Msp。本发明还涉及利用 Msp 进行多核苷酸鉴定。
  • Mutant CsgG pores
    申请人:Oxford Nanopore Technologies Ltd.
    公开号:US10400014B2
    公开(公告)日:2019-09-03
    The invention relates to mutant forms of the outer membrane-located lipoprotein CsgG, in particular, modifications at one or more of positions Tyr51; Asn55; and Phe56. The invention also relates to analyte detection and characterisation using said mutant CsgG.
    本发明涉及外膜定位脂蛋白 CsgG 的突变形式,特别是在 Tyr51、Asn55 和 Phe56 位置上的一个或多个修饰。本发明还涉及使用所述突变 CsgG 进行分析物检测和表征。
  • Hetero-pores
    申请人:Oxford Nanopore Technologies Ltd.
    公开号:US10472673B2
    公开(公告)日:2019-11-12
    The invention relates to hetero-oligomeric pores derived from Msp. The invention also relates to polynucleotide characterisation using the hetero-oligomeric pores.
    本发明涉及由 Msp 衍生的异质异构孔。本发明还涉及利用异构体孔隙表征多核苷酸。
  • Method for modifying a template double stranded polynucleotide using a MuA transposase
    申请人:Oxford Nanopore Technologies Ltd.
    公开号:US10570440B2
    公开(公告)日:2020-02-25
    The invention relates to a method for modifying a template double stranded polynucleotide, especially for characterisation using nanopore sequencing. The method produces from the template a plurality of modified double stranded polynucleotides. These modified polynucleotides can then be characterised.
    本发明涉及一种修饰模板双链多核苷酸的方法,特别是用于利用纳米孔测序进行表征。该方法可从模板中产生多个经修饰的双链多核苷酸。然后可以对这些修饰的多核苷酸进行表征。
  • Sample preparation method
    申请人:Oxford Nanopore Technologies Ltd.
    公开号:US10669578B2
    公开(公告)日:2020-06-02
    The invention relates to an improved method for characterising a template polynucleotide. The method involves using a polymerase to prepare a modified polynucleotide which makes it easier to characterise than the template polynucleotide.
    本发明涉及一种表征模板多核苷酸的改进方法。该方法包括使用聚合酶制备修饰的多核苷酸,使其比模板多核苷酸更容易表征。
查看更多

同类化合物

腺苷-3’-磷酸 胸苷酰-(3'-5')-胸苷氰基乙基磷酰三酯 胸腺嘧啶脱氧核苷3-单磷酸铵盐水合物 胞啶-3'-单磷酸二钠盐 环(腺苷酰(3'-5')尿苷单磷酸酯) 尿苷酸 尿苷溴乙酰甲醇5'-二磷酸酯 尿苷氯乙酰甲醇5'-二磷酸酯 丁二酸,甲基-,1-(苯基甲基)酯,(2R)-(9CI) [(2R,3S,4R,5R)-5-(6-氨基嘌呤-9-基)-4-羟基-2-(羟基甲基)四氢呋喃-3-基]苯基磷酸氢酯 [(2R,3S,4R,5R)-5-(2-氨基-6-氧代-3H-嘌呤-9-基)-2-[(2-甲酰基苯氧基)甲基]-4-羟基四氢呋喃-3-基]磷酸二氢酯 N-苯甲酰基-2'-脱氧-3'-胞苷酸2-氯苯基2-氰基乙基酯 8-[(E)-苄亚基氨基]-2'-脱氧腺苷3'-(磷酸二氢酯) 5-甲基-2'-脱氧胞苷-3'-磷酸 3'-(二氢磷酸)鸟嘌呤核苷 3'-(1-丁基磷酰)腺苷 2ˊ-脱氧胞苷-3ˊ-一磷酸 2-脱氧腺苷-3-单磷酸酯*铵 2'-脱氧鸟苷 3'-(磷酸二氢酯) 2'-脱氧腺苷酰-(3'-5')-2'-脱氧腺苷酰-(3'-5)-2'-脱氧腺苷 2'-脱氧-3'-胞苷酸二钠盐 2' -脱氧3' -磷酸游离酸 [3']thymidylic acid mono-[4-(2-iodo-acetylamino)-phenyl] ester 5-Fluor-1-β-D-arabinofuranosylcytosin-3'-phosphat [3']thymidylic acid mono-[4-(2-bromo-acetylamino)-phenyl] ester O2'-Methylguanosin-3'-phosphorsaeure uridine-3'-(2-cyanoethyl)phosphate [3']thymidylic acid mono-[4-(2-chloro-acetylamino)-phenyl] ester (1R)-1-(6-amino-purin-9-yl)-O3-phosphono-1,5-anhydro-D-glucitol Thymidin-3'-(2,4-dinitrophenyl)phosphat N4-Dimethylamino-methylen-2',5'-bis-O-(1-ethoxy-ethyl)-cytidin-3'-phosphat (2R)-3-((hydroxy(((2R,3S,5R)-2-(hydroxymethyl)-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-3-yl)oxy)phosphoryl)oxy)propane-1,2-diyl dioleate 3-Methyl-uridin-3'-phosphat 2'-O-(tert-butyldimethylsilyl)inosine 3'-(allyl 2-cyanoethylphosphate) 2'-O-(2-tetrahydrofuranyl)-N4-(4-anisoyl)cytidine-3'-(2-chlorophenoxy)phosphoryl-2'-O-(2-tetrahydrofuranyl)-N4-(4-anisoyl)cytidine-3'-(2-chlorophenoxy)phosphoryl-2'-O-(2-tetrahydrofuranyl)-N4-(4-anisoyl)cytidine-3'-(2-chlorophenoxy)phosphoryl-2'-O-(2-tetrahydrofuranyl)-N4-(4-anisoyl)cytidine-3'-[O-(2-cyanoethyl)(2-chlorophenyl)phosphate] Phosphoric acid mono-[(2S,5R)-5-(2,4-diamino-pyrrolo[2,3-d]pyrimidin-7-yl)-2,5-dihydro-furan-2-ylmethyl] ester; compound with triethyl-amine 9-β.D-Glucopyranosyl-adenin-4'-phosphat 4-Oxo-pentanoic acid (2R,3S,5R)-3-[(2-chloro-phenoxy)-hydroxy-phosphoryloxy]-5-(5-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-tetrahydro-furan-2-ylmethyl ester N(4),O(2')-Dibenzoyl-cytidin-3'-phosphat cis-((5-((4-amino-2-oxopyrimidin-1(2H)-yl)methyl)-1,3-oxathiolan-2-yl)methyl) (2R,3S,5R)-2-(hydroxymethyl)-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-3-yl hydrogen phosphate 1,20-(icosanedioxy)bis-(3'-phosphatidyl-2'-deoxythymidine) 4-N-benzoyl-5'-O-[di(2-cyanoethyloxy)phosphoryl]-2'-deoxycytidylyl-{3'-OP-(2-cyanoethyl)->5'}-6-N-benzoyl-2',3'-di-O-(tert-butyldimethylsilyl)adenosine [3']uridylic acid mono-[1-(5,6-bis-ethoxycarbonylamino-pyrimidin-4-ylamino)-β-D-1-deoxy-ribofuranos-5-yl] ester 1-β-D-Arabinofuranosylcytidin-3'-phosphat OH[AA]AZMB